NC
ANIK icon

nVerses Capital’s Anika Therapeutics ANIK Stock Holding History

nVerses Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$4.94K – 53
2024
Q3 		$4.94K Buy
+200
New +$5.18K ﹤0.01% 931
2024
Q2 		– Sell
-2,900
Closed -$73.7K – 994
2024
Q1 		$73.7K Buy
+2,900
New +$70.2K 0.18% 215

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

nVerses Capital's ANIK Position: Q4 2024 in Review

nVerses Capital sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 200 shares — an estimated $4.94K sold.

nVerses Capital first reported a position in ANIK in Q1 2024 and held it in 2 quarters. The position peaked at $73.7K in Q1 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • nVerses Capital reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 200 Anika Therapeutics shares in Q4 2024, an estimated $4.94K.
  • nVerses Capital first reported a position in Anika Therapeutics in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Anika Therapeutics position peaked at $73.7K in Q1 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.